5248042026-10-015248042026-10-012026-10-015248042026-10-012026-10-01UnitOrDivisionOrSubsidiaryDomain15248042026-10-01UnitOrDivisionOrSubsidiaryDomain1iso4217:INRxbrli:pure524804AUROBINDO PHARMA LIMITEDAUROPHARMANOTLISTEDINE406A01037NewSale or disposal of unit(s)/division(s)/subsidiaryfalse2026-09-3015:30:002026-10-01A1 Biochem Labs (India) Private Limited, a step down subsidiary of the Company.SubsidiaryA1 Biochem Labs (India) Private Limited000000002026-07-232026-09-30CashA1 Biochem Labs (India) Private Limited (A1 Labs) has received INR 9.18 Cr. for the allotment of equity shares and INR 24.62 Cr. for the allotment of Compulsory Convertible Debentures from Dr. Rajendra Gadikota and allotted 89,94,500 equity shares and 2,41,05,500 Compulsory Convertibles Debentures to him and completed all the formalities on September 30, 2026. Post allotment, Apitoria is holding 80% stake and Dr. Rajendra Gadikota is holding 20% stake in A1 Labs.Dr. Rajendra Gadikota is the former promoter of A1 Biochem Group. As part of the acquisition of A1 Biochem Group by Apitoria, it is agreed that Dr. Rajendra Gadikota will hold 20% stake (on a fully diluted basis) in A1 Labs. Further, Apitoria has the option available to acquire this 20% stake in future as per the agreed terms in the definitive agreements. Dr. Rajendra Gadikota is not related to the promoter /promoter group/group companiesfalsetrue2026-07-23falsetruetrueRegulation 37A of LODR Regulations is not applicable as there is no sale/lease/disposal of undertaking. Further, the transaction will not fall under the definition of ‘Undertaking’ provided in the regulation. New Securities have been issued by A1 Labs as agreed in the terms of the definitive agreements entered into as part of acquisition of A1 Biochem Group. However, it is clarified that A1 Labs had obtained its shareholders’ approval as part of the process of offer and issuance of Securities to Dr. Rajendra Gadikota (dilution of 100% stake in the subsidiary).falseRegulation 37A of LODR Regulations is not applicable as there is no sale/lease/disposal of undertaking. Further, the transaction will not fall under the definition of ‘Undertaking’ provided in the regulation. New Securities have been issued by A1 Labs as agreed in the terms of the definitive agreements entered into as part of acquisition of A1 Biochem Group. However, it is clarified that A1 Labs had obtained its shareholders’ approval as part of the process of offer and issuance of Securities to Dr. Rajendra Gadikota (dilution of 100% stake in the subsidiary).